Gilead Sciences

Phone: +16505743000, 800-GILEAD-5 (800-445-3235)

Fax: (650) 578-9264

E-mail: public_affairs@gilead.com, corporate_development@gilead.com

Web: https://www.gilead.com

Type	Public
Traded as	Nasdaq: GILD NASDAQ Biotechnology Component NASDAQ-100 Component S&P 100 Component S&P 500 Component
Industry	Pharmaceutics Biotechnology
Founded	June 22, 1987 (1987-06-22)
Headquarters	Foster City, California, United States
Area served	Worldwide
Key people	Daniel O'Day (CEO and Chairman) Andrew Dickinson (CFO) Tomáš Cihlář (Vice president, and Senior Director, Biology)
Products	AmBisome Atripla Biktarvy Complera Cayston Descovy Emtriva Epclusa Genvoya Harvoni Hepsera Letairis Lexiscan Macugen Odefsey Ranexa Sovaldi Stribild Tamiflu Truvada Tybost Veklury Vemlidy Viread Vosevi Yescarta Zydelig
Revenue	US$27.31 billion (2021)
Operating income	US$9.92 billion (2021)
Net income	US$6.23 billion (2021)
Total assets	US$67.95 billion (2021)
Total equity	US$21.06 billion (2021)
Number of employees	14,400 (2021)

At Gilead, we’re committed to creating possible. For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases. Through bold and transformative science, we’re creating possibilities that have the potential to become the next generation of life-changing medicines. Our ambition is evident in our mission. Because the impossible is not impossible. It’s what’s next.

For detailed contact information visit location pages below.